Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ares Capital Corporation (ARCC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ares Capital Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.42 (market cap $29.60B), while Ares Capital Corporation trades at $19.87 (market cap $14.34B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.1× Ares Capital Corporation's market cap, and Ares Capital Corporation pays a 9.61% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ARCC | |
|---|---|---|
Market Cap | $29.60B | $14.34B |
Sector | Health | Financials |
52-Week High | $491.22 | $22.68 |
52-Week Low | $205.48 | $17.45 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 9.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
ARCC trades at $19.875, down 0.53% on the day, with strong analyst support showing 24 buy ratings and a consensus price target of $19.63. The stock maintains a bullish technical signal with moving averages supporting upward momentum, though oscillators indicate some near-term pressure. Recent earnings showed Q2 2026 EPS of $0.47, slightly below expectations, while the company continues its 17-year dividend streak with consistent $0.48 quarterly payments.
The outlook remains positive with solid fundamentals including 81.77% net income margin and 6.88% ROE, though investors should monitor declining revenue trends from $1.7B in 2024 to projected $1.2B in 2026. Key risks include private credit market strain and dividend coverage tightening to 104%, while institutional confidence remains high with no sell ratings among 32 analysts covering the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →
